Evidence map›Paper›PMID 42265194›Full record

ArticleLeukemia2026

Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells.

Valeria Bica, Anna Francesca Pacilè, Martin Boettcher, Valentina Marano, Veronica Marabitti, Francesca Nazio, Mirko Cortese, Thomas Fischer, Livia Perfetto, Dimitrios Mougiakakos and 2 more

Abstract read
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Valeria Bica *Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy.ORCID http://orcid.org/0000-0003-3366-5562
Anna Francesca Pacilè *Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy.
Martin BoettcherHealth Campus for Inflammation, Immunity and Infection (GCI3), Otto-von-Guericke University of Magdeburg, Magdeburg, Germany.ORCID http://orcid.org/0000-0003-2911-8830
Valentina MaranoTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, Pozzuoli, 80078, Italy.ORCID http://orcid.org/0009-0002-2182-1302
Veronica MarabittiDepartment of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy.
Francesca NazioDepartment of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy.
Mirko CorteseTelethon Institute of Genetics and Medicine (TIGEM), Via Campi Flegrei 34, Pozzuoli, 80078, Italy.ORCID http://orcid.org/0000-0003-1786-4211
Thomas FischerHealth Campus for Inflammation, Immunity and Infection (GCI3), Otto-von-Guericke University of Magdeburg, Magdeburg, Germany.
Livia PerfettoDepartment of Biology and Biotechnologies "Charles Darwin", University of Rome La Sapienza, Piazzale Aldo Moro 5, 00185, Rome, Italy.
Dimitrios MougiakakosHealth Campus for Inflammation, Immunity and Infection (GCI3), Otto-von-Guericke University of Magdeburg, Magdeburg, Germany.ORCID http://orcid.org/0000-0002-2817-6660
Giorgia MassacciDepartment of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy. giorgiamassacci@hotmail.it.ORCID http://orcid.org/0000-0003-3223-6547
Francesca SaccoDepartment of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica 1, 00133, Rome, Italy. francesca.sacco@uniroma2.it.ORCID http://orcid.org/0000-0001-5586-9529

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 21815Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) 28858Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) E53D23004850006
6 · The paper itself

Abstract

In acute myeloid leukemia (AML), the insertion site of internal tandem duplications (ITDs) within the FLT3 gene critically determines the sensitivity to tyrosine kinase inhibitors (TKIs). Despite recent advances, patients harboring ITDs in the tyrosine kinase domain (TKD) still lack effective therapeutic options. To elucidate the molecular basis underlying the differential TKI sensitivity of FLT3-ITD cells, we integrated high-resolution mass spectrometry-based (phospho)proteomics with subcellular fractionation. Our analysis revealed that midostaurin induces the subcellular redistribution of approximately 2500 proteins involved in crucial biological processes, including cell cycle control, autophagy, and metabolism. Functional analyses further demonstrated that the ITD insertion site determines the autophagy response to midostaurin and modulates mitochondrial metabolism, influencing organelle architecture and ATP production, even at steady state. Importantly, by integrating subcellular proteomic dataset with functional metabolic assays, we uncovered a lipid-dependent vulnerability of FLT3-ITD cells: lipid restriction enhances FLT3 trafficking to the plasma membrane, and markedly reduces cell viability, restoring midostaurin sensitivity of resistant FLT3-ITD cells. Together, our findings reveal that the FLT3-ITD insertion site orchestrates a coordinated remodeling of subcellular protein organization, autophagy, and metabolism, and identify lipid-mediated control of FLT3 compartmentalization as a therapeutically actionable mechanism to overcome TKI resistance in FLT3-ITD AML.

Indexed as

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteOrganellesProteomicsTandem Repeat SequencesAutophagyHumansProtein Kinase InhibitorsStaurosporineFLT3 protein, humanfms-Like Tyrosine Kinase 3midostaurinProtein Kinase InhibitorsStaurosporine

Identifiers

PMID42265194
PMCPMC13421297

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.